{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Oculis Holding AG"},"Symbol":{"label":"Symbol","value":"OCSAW"},"Address":{"label":"Address","value":"Switzerland"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide."},"CompanyUrl":{"label":"Company Url","value":"https://www.oculis.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Ramin Tadayoni","title":"Chief Scientific Officer"},{"name":"Riad Sherif","title":"Chief Executive Officer & Director"},{"name":"Snehal Shah","title":"President-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}